Feed SOLV
SO

Solventum

SOLV · NYSE

$88.86 +1.52% (+$1.33)
1M -2.64%
Market Cap $15.4B
P/E Ratio 10.73x
Div. Yield -
ROE 28.96%
Piotroski F-Score Strong
7/9
Valuation
90 /100
Cheap
EV/EBITDA 7.80x
P/S 1.85x
P/B 3.21x
Growth
28 /100
Declining
Rev. growth 0.79%
Book val. growth 24.52%
EPS growth 4.46%
Profitability
69 /100
Strong
Net margin 17.26%
Op. margin 24.99%
FCF margin 1.42%
Quality
84 /100
Excellent
ROE 28.96%
ROA 10.07%
Asset turnover 0.58x
Debt
57 /100
Moderate
Current ratio 1.02x
Int. coverage 7.38x
Net debt/EBITDA 1.88x
Stability
67 /100
Stable
Rev. volatility 0.09%
EPS volatility 150.17%
Profitable years 4

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about SOLV
Online

About the company

Solventum Corporation is an American technology company that focuses on developing innovative solutions in the fields of chemistry and pharmaceuticals. It specializes in providing services related to research, development, and commercialization of chemical and pharmaceutical products. Solventum Corporation collaborates with pharmaceutical and biotechnology companies to optimize manufacturing processes and develop new active ingredients. The company's goal is to improve the efficiency and safety of chemical processes, with a focus on sustainability and technological innovations.

Sector

Healthcare

Industry

Medical - Instruments & Supplies

CEO

Bryan C. Hanson

Employees

20,584

Headquarters

Eagan

Upcoming events

05 NOV

Earnings

Upcoming earnings report

45d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.